Nicotinamide riboside

Cat. No.: HY-123033: Data Sheet
SDS
Handling Instructions
FAQs
Technical Support

Nicotinamide riboside, an orally active NAD⁺ precursor, increases NAD⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities. Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Nicotinamide riboside chloride) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

CAS No. : 1341-23-7

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Nicotinamide riboside:

Nicotinamide riboside chloride Nicotinamide riboside tartrate Nicotinamide riboside malate

Other Forms of Nicotinamide riboside:

Nicotinamide riboside chloride In-stock
Nicotinamide riboside tartrate In-stock
Nicotinamide riboside malate In-stock
Nicotinamide riboside (triflate) Get quote

25 Publications Citing Use of MCE Nicotinamide riboside

Bio/Physico-chemical Assay

Histological Imaging/Staining

Cell Imaging/Staining

In Vivo Efficacy Study

IHC

2D/3D Cell Culture and Differentiation

Cell Proliferation/Viability Assay

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Jan 26;13(1):18. [Abstract]; Effect of SIRT3 agonist (Nicotinamide riboside chloride; 0-1600 μM) on the proliferation of MC3T3-E1 cells was determined by CCK-8 assay after 2 days of stimulation

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Jan 26;13(1):18. [Abstract]; IF staining of SIRT3, BNIP3, NIX and DRP1 expression in MC3T3-E1 cells treated with DEX and SIRT3 agonist (800 μm).

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Jan 26;13(1):18. [Abstract]; WB analysis of SIRT3, BNIP3, NIX, DRP1, MFN1 and MFN2 expression in MC3T3-E1 cells treated with DEX and SIRT3 agonist (800 μM).

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Res Sq. 2025 Mar 31.; Representative hematoxylin and eosin (H&E)-stained sections of small intestines were collected at the end of the experiment (NR:Nicotinamide riboside,400 mg/kg/day； po for 4 weeks) or vehicle (phosphate buffer; at the same dose and volume as NR) once a day after irradiation exposure in C57BL/6 mouse)

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Res Sq. 2025 Mar 31.; Immunofluorescence detection of Ki-67 and ZO-1 in IECs between groups with NR (Nicotinamide riboside; 0.5 mM; 24 h).

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Res Sq. 2025 Mar 31.; Morphology of the SI and colon (NR:Nicotinamide riboside,400 mg/kg/day； po for 4 weeks) or vehicle (phosphate buffer; at the same dose and volume as NR) once a day after irradiation exposure in C57BL/6 mouse)

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Invest Ophthalmol Vis Sci. 2024 Jul 1;65(8):1. [Abstract]; The effect of different concentrations of NR (Nicotinamide riboside chloride;200,400, 800, 1000 μM) on primary human trabecular meshwork cells' viability after 24 and 72 hours of treatment, was determined by using the CCK-8 assay

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2024 Aug 9:117066. [Abstract]; WB images of SIRT3, AcK68-MnSOD and AcK122-MnSOD expressions in DRG tissues. Quantification of SIRT3, AcK68-MnSOD and AcK122-MnSOD expressions normalized with β-actin expressions and the Saline+Saline treated samples was set to 1 (NR (Nicotinamide riboside chloride); PTX (4 mg/kg, i. p.) Group, PTX (4 mg/kg, i.p.) + NR (400 mg/kg, i.g.) Group, PTX (4 mg/kg, I.P.) + NR (400 mg/kg, i.g.) +3-TYP (50 mg/kg, i.p.) group, NR (400 mg/kg, i.p.) group, 3-TYP (50 mg/kg, i.p.) group in SIRT3 WT mice)

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2024 Aug 9:117066. [Abstract]; The representative images depicting the expression of AcK68-MnSOD in each group were utilized for immunohistochemical detection (NR (Nicotinamide riboside chloride); PTX (4 mg/kg, i. p.) Group, PTX (4 mg/kg, i.p.) + NR (400 mg/kg, i.g.) Group, PTX (4 mg/kg, I.P.) + NR (400 mg/kg, i.g.) +3-TYP (50 mg/kg, i.p.) group, NR(400 mg/kg, i.p.) group, 3-TYP (50 mg/kg, i.p.) group in SIRT3 WT mice)

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Cells. 2023 Oct 2;12(19):2396. [Abstract]; THP-1 cells were supplemented with 200 µM NR (Nicotinamide riboside chloride) for 4 h before treatment with CEES or HN2 in growth medium (“Ctrl”) for 30 min. The “0” refers to solvent control. After exposure, cells were incubated with fresh growth medium with or without 200 µM NR for 20 h, and cell viability was measured with alamarBlue assay

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Commun Biol. 2023 Mar 2;6(1):235. [Abstract]; The cells were pretreated with NR (0.5 µM) for 1 h followed by post-incubation with LPS (1 µg/mL) or H2O2 (100 µM) for 24 h, quantitative analysis of cell viability in each group after LPS stimulation and H2O2 stimulation.

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102507. [Abstract]; MitoParaquat (0.1 μM, 30 min) abolished the inhibition of platelet aggregation by nicotinamide riboside (1 mM, 30 min) or olaparib (20 μM, 30 min) in resting platelets from LST patients.

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102507. [Abstract]; MitoParaquat (0.1 μM, 30 min) did not interrupt the improvements in mitochondrial respiration induced by nicotinamide riboside (1 mM) or olaparib (20 μM) in resting platelets from LST patients.

: Nicotinamide riboside purchased from MedChemExpress. Usage Cited in: Cell Biosci. 2021 Nov 10;11(1):192.; Relative ATP, NAD+, NADH, and NAD+/NADH levels in NR (Nicotinamide ribosid, 100 mM, 24 h) treatment SY5Y cells.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Sirtuin Isoform Specific Products:

View All Isoforms

Sirtuin SIRT1 SIRT2 SIRT3 SIRT6 SIRT5 SIRT7 SIRT4

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Purity & Documentation
References
Customer Review

Description

Nicotinamide riboside, an orally active NAD⁺ precursor, increases NAD⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities^[1]. Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease^[2].

IC₅₀ & Target^[1]

SIRT1

SIRT3

Human Endogenous Metabolite

In Vitro

Nicotinamide riboside (0.5 mM; 24 hours) reduces the acetylation status of Ndufa9 and SOD2^[1].
Nicotinamide riboside increases intracellular and mitochondrial NAD⁺ content in C2C12, Hepa1.6, and HEK293 cells in a concentration-dependent manner at concentrations ranging from 1-1000 μM^[1].
Nicotinamide riboside boosts NAD to restore antiviral poly(ADP-ribose) polymerase (PARP) functions to support innate immunity for coronavirus (CoVs), a cause of COVID-19^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	HEK293T cells
Concentration:	0.5 mM
Incubation Time:	24 hours
Result:	Reduced the acetylation status of Ndufa9 and SOD2.

In Vivo

Chronic Nicotinamide riboside (p.o.; 400 mg/kg/day; for 16 weeks) supplementation increases plasma and intracellular NAD⁺ content in a tissue-specific manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	10-week-old C57Bl/6J mice^[1]
Dosage:	400 mg/kg
Administration:	p.o.; daily; for 16 weeks
Result:	Increased plasma and intracellular NAD⁺ content in a tissue-specific manner.

Clinical Trial

Molecular Weight

255.25

Formula

C₁₁H₁₅N₂O₅

CAS No.

1341-23-7

Appearance

Solid

Color

White to off-white

SMILES

NC(C1=C[N+]([C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)=CC=C1)=O

Structure Classification

Others

Initial Source

Animals

Microorganisms

milk

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Purity & Documentation

Data Sheet (275 KB) SDS (252 KB) Handling Instructions (2659 KB)

References

[1]. Cantó C, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protectsagainst high-fat diet-induced obesity. Cell Metab. 2012 Jun 6;15(6):838-47. [Content Brief]

[2]. Bing Gong, et al. Nicotinamide Riboside Restores Cognition Through an Upregulation of Proliferator-Activated Receptor-γ Coactivator 1α Regulated β-Secretase 1 Degradation and Mitochondrial Gene Expression in Alzheimer's Mouse Models. Neurobiol Aging. 2013 Jun;34(6):1581-8. [Content Brief]

[3]. Collin D Heer, et al. Coronavirus and PARP Expression Dysregulate the NAD Metabolome: A Potentially Actionable Component of Innate Immunity. bioRxiv. 2020 Apr 30;2020.04.17.047480. [Content Brief]